ORGO (Organogenesis Holdings) Other Current Liabilities: $0.0 Mil (As of Mar. 2026)


ORGO Organogenesis Holdings Inc ORGO
67 GF Score
Price $2.47
GF Value $3.08
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Other Current Liabilities?

Organogenesis Holdings ORGO -0.80% 67 Other Current Liabilities is $0.0 Mil as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.08 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's other current liabilities for the quarter that ended in Mar. 2026 was $0.0 Mil.

Organogenesis Holdings's quarterly other current liabilities increased from Sep. 2025 ($33.2 Mil) to Dec. 2025 ($44.0 Mil) but then declined from Dec. 2025 ($44.0 Mil) to Mar. 2026 ($0.0 Mil).

Organogenesis Holdings's annual other current liabilities increased from Dec. 2023 ($19.4 Mil) to Dec. 2024 ($25.3 Mil) and increased from Dec. 2024 ($25.3 Mil) to Dec. 2025 ($44.0 Mil).

Organogenesis Holdings Other Current Liabilities Related Terms

Organogenesis Holdings Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Other Current Liabilities Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.01 18.04 19.37 25.29 43.97

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.98 17.92 33.16 43.97 0.00
ORGO
67GF Score
Organogenesis Holdings Inc ORGO
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.0 Mil mean?
Organogenesis Holdings (ORGO) has a Other Current Liabilities of $0.0 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Organogenesis Holdings.
Is Organogenesis Holdings' Other Current Liabilities too high?
Organogenesis Holdings' current Other Current Liabilities is $0.0 Mil. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Other Current Liabilities compare to TKNO and AKBA?
Organogenesis Holdings' Other Current Liabilities of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Organogenesis Holdings. Organogenesis Holdings's current Other Current Liabilities is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.08, compared to a current price of $2.47 — trading 19.8% below its estimated fair value. The current Other Current Liabilities is $0.0 Mil. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Other Current Liabilities is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.47 is trading 19.8% below its estimated GF Value™ of $3.08. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

  • Other Current Liabilities: $0.0 Mil
  • GF Value™: $3.08 vs. price of $2.47 (19.8% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges 2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for ORGO

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.47
Price
$3.08
GF Value